FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR(R)
COPENHAGEN, Denmark, April 20, 2018 -- (Healthcare Sales & Marketing Network) -- Veloxis Pharmaceuticals A/S announced today that the U.S. Food & Drug Administration (FDA) has accepted for standard review the Company's supplemental New Drug Application (s... Biopharmaceuticals, FDA Veloxis Pharmaceuticals, ENVARSUS, tacrolimus, kidney transplant
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Denmark Health | Kidney Transplant | Kidney Transplantation | Marketing | New Drug Applications | Pharmaceuticals | Prograf | Tacrolimus | Transplant Surgery | Transplants | Urology & Nephrology